Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma

20 Feb 2025

Abstract excerpt

Despite advances in treatments, multiple myeloma (MM) remains an incurable cancer where relapse is common. We developed a circulating tumor DNA (ctDNA) approach in order to characterize tumor genomics, monitor treatment response, and detect early relapse in MM. By sequencing 412 specimens from 64 patients with newly diagnosed or relapsed/refractory disease, we demonstrate the correlation between ctDNA and key...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to CAR-T cell therapy research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39979252
DOI: 10.1038/s41467-025-56486-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myelomaPMID 39979252Read ↗

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read ↗

Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.Semantic proximity Read ↗

Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple MyelomaSemantic proximity Read ↗

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.Semantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor DiseasesSemantic proximity Read ↗

Tracking myeloma tumor DNA in peripheral blood.Semantic proximity Read ↗

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.Semantic proximity Read ↗

MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma PathologySemantic proximity Read ↗

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.Semantic proximity Read ↗

Analysis of Circulating Tumor DNA.Semantic proximity Read ↗

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Semantic proximity Read ↗

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.